DKN 01

Drug Profile

DKN 01

Alternative Names: DKN-01; LY-2812176

Latest Information Update: 21 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Developer Leap Therapeutics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action DKK1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Gastric cancer; Multiple myeloma; Oesophageal cancer
  • Phase I Biliary cancer; Non-small cell lung cancer

Most Recent Events

  • 21 Nov 2017 DKN 01 is still in phase I trials for Non-small cell lung cancer in USA
  • 13 Nov 2017 Phase-I/II clinical trials in Gastric cancer and Oesophageal cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (IV)
  • 13 Nov 2017 Additional efficacy data from a phase I trial in Oesophageal cancer released by Leap Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top